Expression of excision repair cross-complementing 1, topoisomeraseII, ribonucleotide reductase M1, β3-tubulin and thymidylate synthase in lung cancer

Objective To analyze the expression characteristics of excision repair cross-complementing 1(ERCC1), topoisomerase Ⅱ (TOPO Ⅱ), ribonucleotide reductase M1(RRM1), β3-tubulin and thymidylate synthase (TS) in lung cancer and their associations with the pathological types. Methods The immunohistochemical EnVision method was used to determine the expression of ERCC1, TOPOⅡ, RRM1, β3-tubulin and TS in 548 patients who were diagnosed as lung cancer from January 2011 to December 2014. Variance analysis was performed to analyze their expression characteristics among different pathological types and correlation. Results The expression positive rates of ERCC1, TOPOⅡ, RRM1, β3-tubulin and TS were 61.86% (339/548), 91.06% (499/548), 62.59% (343/548), 73.18% (401/548) and 70.44% (386/548), respectively. The expression of ERCC1 was weak positive mostly (P<0.05), meanwhile the expression of TOPO Ⅱ was medium-strong positive mostly (P<0.05). In ERCC1 group, the positive rate of squamous cell carcinoma was higher than that of adenocarcinoma [57.39% (167/291) vs. 42.61% (124/291), P=0.000]. In weak positive of TOPOⅡ group, the proportion of adenocarcinoma was higher than that of squamous cell carcinoma[23.58% (100/137) vs. 8.73% (37/137), P=0.000]. In medium-strong positive of TOPO Ⅱ group, the proportion of squamous cell carcinoma was higher than that of adenocarcinoma[47.41% (201/287/) vs. 20.28% (86/287), P=0.000]. The expressions of ERCC1, TOPO Ⅱ, RRM1, β3-tubulin and TS were irrelevant (r=0.4, P=0.397). Conclusions The expressions of ERCC1 and TOPO Ⅱ are higher in squamous cell carcinoma than those in adenocarcinoma. The expression of ERCC1 is weak positive mostly, meanwhile the expression of TOPO Ⅱ is medium-strong positive mostly. There is no correlation between them. Key words: Lung neoplasms; Excision repair cross-complementing 1; Topoisomerase Ⅱ; Thymidylate synthase